Skip to main content

Year: 2026

Great Elm Capital Corp. Announces First Quarter 2026 Financial Results

Company to Host Conference Call and Webcast at 8:30 AM ET on May 5, 2026 Jason Reese, Executive Chairman of the Board of Directors, Appointed as CEO of the Company GECC’s Investment Adviser Waives 2Q26 Incentive Fees, Following the Waiver of $2.8 Million, or $0.20 Per Share, of Accrued Incentive Fees through March 31, 2026 Net Investment Income (“NII”) of $0.36 Per Share in 1Q26 Grew Approximately 13% Quarter-over-Quarter NAV of $7.74 Per Share as of March 31, 2026 Called or Repurchased All $57.5 Million of GECCO Notes due June 2026, Leaving No Funded Debt Maturity Until 2029 Strong Liquidity Position with Approximately $10 Million of Cash and Equivalents, $50 Million of Revolving Credit Facility Availability, and Ample Liquid Assets as of March 31, 2026 Repurchased Approximately 1% of GECC’s Outstanding Shares at an Average 36%...

Continue reading

Firefly Aerospace Announces First Quarter 2026 Financial Results

Completed critical milestones for Blue Ghost, successfully returned Alpha to flight, and recently selected to support the Golden Dome Space-Based Interceptor programFirefly’s battle-tested AI software supports missile defense warning and tracking applications. CEDAR PARK, Texas, May 04, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today issued financial results for the first quarter ended March 31, 2026. “With another quarterly revenue record, momentum defined Firefly’s first quarter of 2026 – we were selected to support the space-based interceptor program under Golden Dome, achieved critical milestones for our Blue Ghost lunar missions, successfully launched Alpha Flight 7, and completed a tactically responsive space demonstration for...

Continue reading

Devon Energy and Coterra Energy Shareholders Approve Merger

OKLAHOMA CITY and HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) — Devon Energy Corporation (“Devon”) (NYSE: DVN) and Coterra Energy Inc. (“Coterra”) (NYSE: CTRA) today announced that shareholders of both companies approved all proposals required to complete the previously announced all-stock merger between Devon and Coterra. The merger is expected to close on or around May 7, 2026. At the special meeting of Devon shareholders held today, more than 76 percent of the shares of Devon common stock were represented, and more than 98 percent of the votes cast were in favor of the transaction. At the special meeting of Coterra shareholders held today, more than 82 percent of the shares of Coterra common stock were represented, and more than 99 percent of the votes cast were in favor of the transaction. “We are pleased with the strong support...

Continue reading

InspireMD Reports First Quarter 2026 Financial Results

            – Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% – – Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures –             – FDA approval of the original CGuard delivery system anticipated in Q3 2026 – – On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company’s addressable market – MIAMI, May 04, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2026. Recent Business...

Continue reading

onsemi Reports First Quarter 2026 Results

Year-over-year operating income growth outpaces revenue growth by 2x SCOTTSDALE, Ariz., May 04, 2026 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its first quarter 2026 results with the following highlights:Revenue of $1,513 million, exceeding the midpoint of our guidance GAAP and non-GAAP gross margin of 38.5% GAAP operating margin of (3.5)% and non-GAAP operating margin 19.1% GAAP diluted loss per share of ($0.08) and non-GAAP diluted earnings per share $0.64 Share repurchases of $346 million, representing approximately 160% of free cash flow“We exceeded expectations as demand strengthened through the quarter and we have moved beyond the cyclical trough on a path to recovery. Our AI data center business accelerated, growing more than 30% sequentially.” said Hassane El‑Khoury, President and CEO of...

Continue reading

James River Announces First Quarter 2026 Results

CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) — Chapel Hill, N.C., May 4, 2026 – James River Group Holdings, Inc. (“James River” or the “Company”) (NASDAQ: JRVR) today reported the following results for the first quarter of 2026 as compared to the same period in 2025:  Three Months EndedMarch 31,   Three Months EndedMarch 31,($ in thousands, except for share data)   2026     per diluted share     2025     per diluted shareNet (loss) income from continuing operations available to common shareholders $ (10,743 )   $ (0.23 )   $ 9,019     $ 0.18  Net loss from discontinued operations1   (149 )   $ —       (1,414 )   $ (0.02 )Net (loss) income available to common shareholders   (10,892 )   $ (0.23 )     7,605     $ 0.16  Adjusted net operating income2   5,806     $ 0.12       9,102     $ 0.19  Unless...

Continue reading

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Reported early rinzimetostat data in post-AR inhibitor mCRPC, demonstrating promising durability and reinforcing rinzimetostat’s potential to restore and sustain the benefit derived from AR inhibitors Anticipate rinzimetostat program update in 2H 2026 and several enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately...

Continue reading

Adeia Announces First Quarter 2026 Financial Results

Signed new license agreements with AMD and MicrosoftGenerated $58 million in cash from operations and achieved 60% adjusted EBITDA marginPaid down debt by $28 million bringing our outstanding balance to less than $400 million SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to 2026, delivering first quarter revenue of $105 million, generating $58 million in operating cash flow, and maintaining strong profitability with a 60% adjusted EBITDA margin,” said Paul E. Davis, chief executive officer of Adeia. “We closed eight license agreements during the quarter, three of which were with new customers, including multi-year agreements with AMD and Microsoft. We believe our deal execution...

Continue reading

Gaia Reports First Quarter 2026 Financial Results

BOULDER, Colo., May 04, 2026 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary vs First Quarter 2025 (where applicable)Revenue increased to $24.3 million compared to $23.8 million. Gross profit remained flat at $20.9 million. Generated $1.5 million in operating cash flow and $1.1 million in free cash flow.Management Commentary “This quarter reflects a deliberate step in how we are positioning Gaia for long-term success,” said Kiersten Medvedich, Chief Executive Officer of Gaia. “As we’ve evaluated the business, it has become clear that our greatest opportunity lies in deepening our direct relationship with members, where we can deliver the full Gaia experience and capture significantly stronger...

Continue reading

EverQuote Announces First Quarter 2026 Financial Results

Grows Q1 revenue 15% year-over-year to $190.9 million Delivers net income of $18.7 million Drives record Adjusted EBITDA of $29.3 million, marking growth of 30% year-over-year Exceeds guidance across all metrics Provides Q2 outlook reflecting 21% revenue growth at the midpointCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading provider of growth solutions for property and casualty, or P&C, insurance providers, today announced financial results for the first quarter ended March 31, 2026. “Our first quarter results demonstrate our strong performance and favorable sector demand as we execute our mission to empower P&C insurance providers to grow market share by maximizing customer acquisition across digital channels,” said Jayme Mendal, CEO of EverQuote. “As we look to the remainder...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.